OpenNashEarnings

McKesson (MCK) · Health Care

McKesson Q1 FY2027 earnings: summary, key numbers & outlook

Results filed 5 Aug 2026 · Quarter ended 30 Jun 2026

Slides (33 pages)Official transcript (PDF) ↗Press release ↗Investor relations ↗

Summaries and transcripts are machine-generated and can contain errors.

In brief

McKesson named its future standalone Medical-Surgical business Wellverse and sold about 13% of it to Apollo Funds for $1.25 billion, advancing the planned separation.

McKesson's growth this quarter came from specialty medicines and oncology. North American Pharmaceutical gained from higher prescription volumes, especially specialty products sold to health systems and strategic accounts. Oncology & Multispecialty grew on provider solutions, specialty distribution and acquisitions. Prescription Technology Solutions saw higher demand for access solutions. Medical-Surgical Solutions grew across alternate sites of care but earned less on product mix and one-time administrative costs.

Management is concentrating on oncology, multispecialty and biopharma services while preparing to spin off Medical-Surgical Solutions as Wellverse. The company funded the separation with a $2.25 billion Term Loan B and the Apollo investment. It also plans about $5.0 billion of share repurchases this year. The main risk is that the separation may not close on the planned terms or timeline, or deliver the intended benefits.

Slides & documents

Open the slide deck (PDF, 33 pages) ↗

McKesson Q1 FY2027 slide deck, page 1McKesson Q1 FY2027 slide deck, page 2McKesson Q1 FY2027 slide deck, page 3McKesson Q1 FY2027 slide deck, page 4McKesson Q1 FY2027 slide deck, page 5McKesson Q1 FY2027 slide deck, page 6

Showing the first 6 of 33 pages.

From McKesson investor relations

SEC filing

Key numbers

Revenues · GAAP
$105.4 billion

up 8% from a year ago

Net income attributable to McKesson · GAAP
$614.0M

down 22% from $784 a year ago

Diluted EPS · GAAP
$5.15

down $1.10 from a year ago

Adjusted EPS · non-GAAP
$9.93

up 20% from a year ago

Operating income · GAAP
1.3B

up 27% from a year ago

Net cash used in operating activities · GAAP
-$220.0M

compared with $(918) a year ago

Free cash flow · non-GAAP
-$372.0M

compared with $(1,107) a year ago

Segment or metricValueChange
North American Pharmaceutical revenue$86.8 billionup 5%
Oncology & Multispecialty revenue$14.2 billionup 33%
Prescription Technology Solutions revenue$1.6 billionup 9%
Medical-Surgical Solutions revenue$2.8 billionup 4%
Oncology & Multispecialty adjusted segment operating profit$405 millionup 41%
Where each number comes from
  • Revenues: “First quarter revenues were $105.4 billion, an increase of 8% from a year ago, driven by growth in the North American Pharmaceutical and Oncology & Multispecialty segments”
  • Net income attributable to McKesson: “Net income attributable to McKesson Corporation | $614 | $784 | (22)% Earnings per common share attributable to McKesson Corporation (a) Diluted | $5.15 | $6.25 | (18)%”
  • Diluted EPS: “Earnings per diluted share of $5.15 decreased $1.10. •Adjusted Earnings per Diluted Share of $9.93 increased 20%.”
  • Adjusted EPS: “Earnings per diluted share of $5.15 decreased $1.10. •Adjusted Earnings per Diluted Share of $9.93 increased 20%.”
  • Operating income: “Gross profit | 3,685 | 3,279 | 12 Selling, distribution, general, and administrative expenses | (2,264) | (2,196) | 3 Claims and litigation charges, net | 34 | — | — Restructuring, impairment, and related charges, net | (136) | (47) | 189 Total operating expenses | (2,366) | (2,243) | 5 Operating income | 1,319 | 1,036 | 27”
  • Net cash used in operating activities: “Net cash used in operating activities | $(220) | $(918) | (76)% Net cash used in investing activities | (214) | (3,564) | (94)”
  • Free cash flow: “Payments for property, plant, and equipment | (112) | (111) | 1 Capitalized software expenditures | (40) | (78) | (49) Free Cash Flow (Non-GAAP) | $(372) | $(1,107) | (66)%”
  • North American Pharmaceutical revenue: “North American Pharmaceutical Segment •Revenues were $86.8 billion, an increase of 5%, driven by increased prescription transaction volumes, including higher volumes from specialty products”
  • Oncology & Multispecialty revenue: “Oncology & Multispecialty Segment •Revenues were $14.2 billion, an increase of 33%, driven by growth in provider solutions and specialty distribution, including contributions from acquisitions.”
  • Prescription Technology Solutions revenue: “Prescription Technology Solutions Segment •Revenues were $1.6 billion, an increase of 9%, driven by increased prescription volumes in third-party logistics and access solutions.”
  • Medical-Surgical Solutions revenue: “Medical-Surgical Solutions Segment •Revenues were $2.8 billion, an increase of 4%, driven by growth across alternate sites of care, led by higher volumes of specialty pharmaceuticals.”
  • Oncology & Multispecialty adjusted segment operating profit: “Adjusted Segment Operating Profit was $405 million, an increase of 41%, driven by growth in provider solutions and specialty distribution, including contributions from acquisitions.”

Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.

From the filingQ1 FY2027vs year agovs last quarter
Revenue$105.4B+7.7%+9.4%
Operating income$1.3B+27.3%−38.7%
Net income$614.0M−21.7%−63.5%
Diluted EPS$5.15−17.6%—
Free cash flow-$332.0M+67.7%—
Gross margin3.5%+0.1 pts−0.7 pts
Operating margin1.3%+0.2 pts−0.9 pts

Calculated by code from XBRL, not by the model.

Outlook

MetricPeriodOutlook
Adjusted EPSfiscal 2027$44.20 to $45.00
Revenue growthfiscal 20275% to 9% growth
Adjusted operating profit growthfiscal 20279% to 13% growth
Effective tax ratefiscal 202718% to 19%
Free cash flowfiscal 2027$4.5 to $4.9 billion

Key takeaways

  1. Medical-Surgical business gets name and outside investor

    McKesson unveiled Wellverse as the name of the future standalone Medical-Surgical Solutions business. It also sold about 13% of the unit to Apollo Funds for $1.25 billion, which moves the planned separation forward.

  2. Specialty medicines drive pharmaceutical distribution growth

    North American Pharmaceutical gained from higher specialty product volumes, particularly to health systems and strategic accounts, and from the timing of new product launches. Branded pharmaceuticals contributed less.

  3. Oncology & Multispecialty is the fastest-growing segment

    Growth came from provider solutions and specialty distribution, including contributions from acquisitions. Management says it will make focused investments to speed up oncology, multispecialty and biopharma services.

  4. Access solutions demand lifts technology segment

    Prescription Technology Solutions saw higher demand for access solutions and more prescription volume in third-party logistics. Restructuring and impairment charges fell mainly in this segment.

  5. Medical-Surgical earned less despite growth in alternate sites

    Revenue grew across alternate sites of care, led by specialty pharmaceuticals and helped by the extended care channel. Adjusted segment operating profit fell 20% on product mix and one-time administrative expenses.

Charts

Revenue$105.4B+7.7% y/yQ1 FY27
Q3 FY25: $95.3BQ3 25$95.3BQ4 FY25: $90.8B (worked out from the annual figure)Q4 25$90.8BQ1 FY26: $97.8BQ1 26$97.8BQ2 FY26: $103.2BQ2 26$103.2BQ3 FY26: $106.2BQ3 26$106.2BQ4 FY26: $96.3B (worked out from the annual figure)Q4 26$96.3BQ1 FY27: $105.4BQ1 27$105.4BQ2 FY27: $111.0BQ2 27$111.0B

Fourth quarter worked out from the annual figure.

Data
Q3 FY25$95.3B
Q4 FY25$90.8B *
Q1 FY26$97.8B
Q2 FY26$103.2B
Q3 FY26$106.2B
Q4 FY26$96.3B *
Q1 FY27$105.4B
Q2 FY27$111.0B
Diluted EPS (GAAP)$5.15−17.6% y/yQ1 FY27
Q3 FY25: $6.95Q3 25$6.95Q1 FY26: $6.25Q1 26$6.25Q2 FY26: $8.92Q2 26$8.92Q3 FY26: $9.59Q3 26$9.59Q1 FY27: $5.15Q1 27$5.15Q2 FY27: $10.44Q2 27$10.44
Data
Q3 FY25$6.95
Q1 FY26$6.25
Q2 FY26$8.92
Q3 FY26$9.59
Q1 FY27$5.15
Q2 FY27$10.44

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin1.3%+0.2 pts y/yQ1 FY27
Q3 FY25: 1.3%Q3 251.3%Q4 FY25: 1.8%Q4 251.8%Q1 FY26: 1.1%Q1 261.1%Q2 FY26: 1.4%Q2 261.4%Q3 FY26: 1.5%Q3 261.5%Q4 FY26: 2.2%Q4 262.2%Q1 FY27: 1.3%Q1 271.3%Q2 FY27: 1.4%Q2 271.4%
Data
Q3 FY251.3%
Q4 FY251.8%
Q1 FY261.1%
Q2 FY261.4%
Q3 FY261.5%
Q4 FY262.2%
Q1 FY271.3%
Q2 FY271.4%
Free cash flow-$332.0M+67.7% y/yQ1 FY27
Q3 FY25: -$2.5BQ3 25-$2.5BQ4 FY25: $7.6BQ4 25$7.6BQ1 FY26: -$1.0BQ1 26-$1.0BQ2 FY26: $2.3BQ2 26$2.3BQ3 FY26: $1.1BQ3 26$1.1BQ4 FY26: $3.3BQ4 26$3.3BQ1 FY27: -$332.0MQ1 27-$332.0MQ2 FY27: $3.0BQ2 27$3.0B
Data
Q3 FY25-$2.5B
Q4 FY25$7.6B
Q1 FY26-$1.0B
Q2 FY26$2.3B
Q3 FY26$1.1B
Q4 FY26$3.3B
Q1 FY27-$332.0M
Q2 FY27$3.0B

Operating cash flow minus capital expenditure, from cash flow statements.

Questions

What is Wellverse?

Wellverse is the name McKesson announced on August 5, 2026 for the future standalone Medical-Surgical Solutions business. It reflects continued progress toward the planned separation.

Who is investing in McKesson's Medical-Surgical Solutions business?

On June 1, 2026, McKesson sold an approximately 13% minority interest in the business to Apollo Funds for $1.25 billion. On June 9 it also set up a $2.25 billion secured Term Loan B in support of the separation.

Where is McKesson's demand growth coming from?

Growth is coming from specialty products sold to health systems and strategic accounts, oncology provider solutions and specialty distribution including acquisitions, and access solutions in Prescription Technology Solutions.

Which business is under pressure?

Medical-Surgical Solutions saw adjusted segment operating profit fall 20%, on product mix and one-time administrative expenses, partly offset by the extended care channel.

What did McKesson change in its outlook and capital plans?

It raised fiscal 2027 adjusted EPS guidance to $44.20 to $45.00 from $43.80 to $44.60. It plans about $5.0 billion of share repurchases this year and raised the quarterly dividend 15% to $0.94 per share.